KLOW

Description

Scientific overview

KLOW is a fixed-composition, four-peptide blend supplied for laboratory research. Each vial contains GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg, providing a total nominal peptide content of 80 mg.

GHK-Cu is a copper-binding tripeptide complex investigated in fibroblast cultures and animal models for signaling associated with extracellular-matrix synthesis and remodeling. BPC-157 is a synthetic pentadecapeptide studied predominantly in preclinical models. TB-500 is an acetylated thymosin-beta-4-derived peptide fragment studied in analytical, cell, and animal research. KPV is a tripeptide fragment of alpha-melanocyte-stimulating hormone investigated in preclinical laboratory models.

The four components have distinct molecular identities and should be evaluated accordingly. Findings for an individual component do not establish the behavior, safety, or efficacy of the fixed combination.

Research characteristics

• Molecular class: multi-peptide research blend
• GHK-Cu content: 50 mg
• BPC-157 content: 10 mg
• TB-500 content: 10 mg
• KPV content: 10 mg
• Total peptide content: 80 mg
• Research focus: peptide signaling, extracellular-matrix biology, and controlled in-vitro or analytical investigation
• Evidence context: research on these components is largely preclinical; this blend is not an approved clinical product

Research-use notice: Supplied for laboratory research only. Not for human or veterinary use, diagnosis, treatment, or consumption. No medical or therapeutic claims are made.